This is also supported by the 2021 glioma classification, which designates GBM specifically as IDH-wildtype glioma, with what was previously considered secondary GBM now classified as IDH-mutant astrocytoma.[11]. This evidence concerns the gene IDH1 and central nervous system cancer.